Normal ranges for PSA, PSA density, and MRI-assessed prostate volume in healthy males from Germany
By
Maximilian Lindholz
Ivo G. Schoots
Robin Bülow
Patrick Asbach
Marc Kölln
Saskia Nolte
Salina Alaro
Richard Ruppel
Norbert Hosten
Tobias Penzkofer
Charlie A. Hamm
September 25, 2026
Clinical Scorecard: Normal ranges for PSA, PSA density, and MRI-assessed prostate volume in healthy males from Germany
At a Glance
Category Detail
Condition Prostate-specific antigen (PSA) assessment Key Mechanisms PSA, prostate volume (PV), and PSA density (PSAD) are biomarkers for prostatic diseases. Target Population Healthy males aged 20-79 years from Northeast Germany Care Setting Population-based cohort study
Key Highlights
Establishes normative reference values for PSA, PV, and PSAD. MRI provides more accurate PV measurements compared to TRUS. Age-adjusted values are recommended for PSA decision-making. PSAD enhances prostate cancer risk stratification. Study utilizes a bias-free cohort without known prostate diseases. Guideline-Based Recommendations
Diagnosis
Incorporate age-adjusted values for PSA. Management
Use PSAD to inform MRI referral and biopsy decisions. Monitoring & Follow-up
Consider physiological variability in PSA levels. Risks
Fixed PV thresholds may lead to false-negative results. Patient & Prescribing Data
Men without reported prostate disease.
Participants excluded if diagnosed with PCa, LUTS, or BPH.
Clinical Best Practices
Utilize MRI for accurate PV assessment. Apply generalized additive models for better statistical analysis of PSA and PV. Related Resources & Content
